Meet Philippe Lopes-Fernandes
Executive Vice President and Chief Business Office
“Breakthroughs happen when we collaborate with partners who share our commitment to science, patients and delivering impact. Partnering to us, means following the right science, combining our strengths with those of our partners, and using our unique capabilities to ensure medicines reach patients, faster. Our alliances are deeply personal and built for the long term. Together, we know we go further.”
Philippe joined Ipsen in 2020, bringing over 20 years of leadership in global business development and acquisitions, spearheading deals across Europe, North America, and Asia, with senior BD roles at Merck KGaA. He received his degree from the Institut Supérieur de Gestion (ISG), is a French External Trade advisor (Conseiller du Commerce Extérieur), and board member of several companies. Philippe is responsible for driving Ipsen’s external innovation strategy and strengthening alliances across its key therapeutic areas of oncology, neuroscience, and rare disease. Since joining, he has played an instrumental role in delivering high-impact partnerships and M&As, contributing to the addition of over 30 new assets to Ipsen’s pipeline since 2020 and helping to strengthen its global innovation network.
Learn more about Philippe Lopes-Fernandes
Meet David Jenkins
Senior Vice President, Head of Research & External Innovation
“Having started my career as a scientist, I’ve seen firsthand how collaboration can transform science into real-world impact. Our science-led approach to partnering means we seek out the boldest ideas and the greatest minds to drive innovation in areas of high unmet medical need. Every new partnership is built on a shared ambition and a clear vision: delivering medicines to patients that make a real difference.”
David joined Ipsen in 2018, with over 20 years of biotech and industry experience. He previously led TESARO’s immune-oncology translational research and development activities, advancing pioneering programs together with academic and industrial collaborators, as well as holding positions within Research and Development at AstraZeneca/MedImmune and Novartis. He received his MA PhD in Molecular Pharmacology from the University of Cambridge in the UK. At Ipsen, David oversees the external innovation strategy within research and development, focusing on partnership opportunities at all stages of `strategy across oncology, rare disease, and neuroscience. During his time with Ipsen, he has led numerous strategic partnerships that have driven its science-led external innovation strategy – accelerating treatments across established and emerging therapeutic areas at every stage of development.
Learn more about David Jenkins
External Innovation Team
We accelerate the most promising science through external innovation – partnering with biotech and academia to access cutting-edge innovation – combined with our internal R&D expertise.
Contact the partnering team
At Ipsen, entering partnerships is always personal. Our team is committed to success and has the expertise to deliver it. Contact us to see how together, we can accelerate innovation for patients.
David Jenkins
How we work with our partners to accelerate innovation.
Christelle Huguet
How we work with our partners to turn a molecule into a medicine.
Pipeline
Our robust development pipeline, backed by our expertise and external innovation strategy, support patients’ health outcomes across Oncology, Rare Disease, and Neuroscience.